Year |
Citation |
Score |
2014 |
Marquez BV, Ikotun OF, Zheleznyak A, Wright B, Hari-Raj A, Pierce RA, Lapi SE. Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts. Molecular Pharmaceutics. 11: 3988-95. PMID 25058168 DOI: 10.1021/Mp500323D |
0.403 |
|
2014 |
Marquez BV, Ikotun OF, Parry JJ, Rogers BE, Meares CF, Lapi SE. Development of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 1029-34. PMID 24732153 DOI: 10.2967/Jnumed.113.130898 |
0.6 |
|
2014 |
Marquez BV, Zheleznyak A, Lapi SE. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma: where antibody imaging dares to tread. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 708-9. PMID 24665087 DOI: 10.2967/Jnumed.113.136234 |
0.44 |
|
2013 |
Ikotun OF, Marquez BV, Huang C, Masuko K, Daiji M, Masuko T, McConathy J, Lapi SE. Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPET. Plos One. 8: e77476. PMID 24143237 DOI: 10.1371/Journal.Pone.0077476 |
0.351 |
|
2012 |
Marquez BV, Beck HE, Aweda TA, Phinney B, Holsclaw C, Jewell W, Tran D, Day JJ, Peiris MN, Nwosu C, Lebrilla C, Meares CF. Enhancing peptide ligand binding to vascular endothelial growth factor by covalent bond formation. Bioconjugate Chemistry. 23: 1080-9. PMID 22537066 DOI: 10.1021/Bc300114D |
0.638 |
|
2011 |
Aweda TA, Eskandari V, Kukis DL, Boucher DL, Marquez BV, Beck HE, Mitchell GS, Cherry SR, Meares CF. New covalent capture probes for imaging and therapy, based on a combination of binding affinity and disulfide bond formation. Bioconjugate Chemistry. 22: 1479-83. PMID 21755984 DOI: 10.1021/Bc2002049 |
0.59 |
|
2010 |
Day JJ, Marquez BV, Beck HE, Aweda TA, Gawande PD, Meares CF. Chemically modified antibodies as diagnostic imaging agents. Current Opinion in Chemical Biology. 14: 803-9. PMID 20952245 DOI: 10.1016/J.Cbpa.2010.09.015 |
0.506 |
|
Show low-probability matches. |